napsin A aspartic peptidaseGenealiases: KAP · Kdap · NAP1 · NAPA · NR1H2-AS1 · SNAPA
Q-omics provides the consensus-scored NAPSA profile across patient tissues and cancer cell-line models. NAPSA expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, NAPSA is differentially expressed in 11, with the highest sampling consensus in KICH. Additionally, NAPSA protein abundance shows 22,450 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, KICH, and LSCC as cancer lineages where NAPSA shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NAPSA — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NAPSA survival associations across molecular data types. NAPSA RNA expression shows survival associations in the most cancer types (24), followed by mutation status (7) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NAPSA RNA expression–survival associations across cancer types. High NAPSA expression shows unfavorable associations in LUSC and COAD, but favorable associations in KIRC, UVM, BLCA and LUAD. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for NAPSA RNA expression.
This table summarizes NAPSA tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 5. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for NAPSA. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NAPSA shows lower tumor expression in KICH, KIRC, LUSC and LUAD and higher tumor expression in THCA and LIHC. The KICH box plot shows higher NAPSA RNA expression in normal versus tumor tissue (log2 FC = −4.947, t-test p < 0.001).
This table shows molecular features associated with NAPSA in patient tissues and cancer cell lines. In patient samples, NAPSA shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, NAPSA RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BONE.
